Hussain, A., Saad, F., Suzuki, H., Garratt, C., Donica, M., Liu, Y., Imai, K., Fong, P. C. (2026). Phase 1/2 OMAHA-U01 substudy 01A: Oral steroidogenesis inhibitor opevesostat alone or in combination with other therapies in participants with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps5140